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Following kidney donation, short-term quality of life
outcomes compare favorably to US normative data but
long-term effects on mood are not known. In the Renal
and Lung Living Donors Evaluation Study (RELIVE),
records from donations performed 1963–2005 were
reviewed for depression and antidepressant use predo-
nation. Postdonation, in a cross-sectional cohort design
2010–2012, donors completed the Patient Health Ques-
tionnaire (PHQ-9) depression screening instrument, the
LifeOrientationTest-Revised, 36-ItemShort FormHealth
Survey and donation experience questions. Of 6909
eligible donors, 3470 were contacted and 2455 partici-
pated (71%). The percent with depressive symptoms
(8%; PHQ-9> 10) was similar to National Health and
NutritionExaminationSurveyparticipants (7%,p¼ 0.30).
Predonationpsychiatricdisordersweremorecommon in
unrelated than related donors (p¼ 0.05). Postdonation
predictors of depressive symptoms included nonwhite
race OR¼ 2.00, p¼0.020), younger age at donation
(OR¼ 1.33 per 10 years, p¼ 0.002), longer recovery
time from donation (OR¼ 1.74, p¼0.0009), greater
financial burden (OR¼ 1.32, p¼ 0.013) and feeling mor-
ally obligated to donate (OR¼ 1.23, p¼ 0.003). While
cross-sectional prevalence of depression is comparable
to population normative data, some factors identifiable
around time of donation, including longer recovery,
financial stressors, younger age and moral obligation to
donatemay identify donorsmore likely to develop future
depression, providing an opportunity for intervention.
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Introduction
Existing guidelines for donor selection aim to select donors
at low risk for adverse mental health outcomes (1). Yet
donors experience multiple stressors including surgery and
postoperative pain, need for opiate pain medications, social
disruption, time off work with potential financial strain and
decreased exercise while recuperating. In addition, when
recipient and donor rely on the same family members for
assistance during their postoperative recovery, support for
the donor may be attenuated. Each of these factors may
contribute to risk for depression, and numerous studies
have reported that kidney donors may experience short-
term mood changes after kidney donation (1–13). The risk
for developing depression may be mitigated by preexisting
dispositional traits such as an optimistic perception of
outcomes. Optimism has been reported to impact long-
term medical outcomes and is associated with less
depression (14–20). Whether donors with higher optimism
are better equipped towithstand the rigors of donationwith
less distress is unknown.
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The Renal and Lung Living Donors Evaluation Study
(RELIVE) is a research consortium funded by the National
Institute of Allergy, Immunology and Infectious Diseases,
the Health Resources and Services Administration and
the National Heart Lung and Blood Institute to evaluate
intermediate to long-term medical and psychosocial out-
comes of live kidney donors. The study cohort consisted
of 6909 donors who donated between 1963 and 2005,
with follow-up by mailed survey in 2010–2012. In this
cross-sectional study, we aimed to estimate the proportion
of donors with current depressive symptoms, and test
potential predictors of depressive symptoms after
donation.
Methods
The RELIVE study has been described in detail (21,22). This cross-sectional
cohort study specifically addressed risk for depression in donors who
underwent kidney donation between 1963 and 2005 at one of three large US
centers: Mayo Clinic, Rochester, MN (Mayo); University of Alabama at
Birmingham, AL (UAB); and University of Minnesota, Minneapolis, MN
(UMN), with a Data Coordinating Center (DCC) at the University of Michigan
and Arbor Research Collaborative for Health, Ann Arbor, MI.
Trained study staff abstracted data from medical records of all living kidney
donors at the three sites (n¼ 8951) including predonation psychiatric history,
use of psychotropic medications, presence of chronic pain and history of
chemical dependency. The data came from standardized chart abstraction
performed at each site, however the actual donor evaluations were not
standardized and occurred prior to our study. Starting with the last available
mailing address, an attempt was made to contact each donor by mail. If the
potential study participant did not respond to the initial letter of invitation
within 2–4 weeks, a second mailing was sent, followed by two to three
telephone calls. Donors who consented to participate completed a short
questionnaire andwere invited to completemore in-depth questionnaires on
medical and psychosocial health status. Survey procedures and character-
istics of RELIVE donors have been reported (21).
Use of validated instruments
The Patient Health Questionnaire (PHQ-9) Depression Scale (23) is widely
used to screen for depression in the medical and general population. The
questionnaire contains nine items including questions on loss of interest,
depressed mood, sleep, appetite and energy changes, low self-worth,
difficulty concentrating, psychomotor activity changes and suicidal ideation.
For each item, responses are scored between 0 and 3, ranging from ‘‘not at
all’’ to ‘‘nearly every day’’; overall scores can range from 0 to 27. Construct
validity and criterion validity have been tested in primary care populations,
with a PHQ-9 score 10 found to have 88% sensitivity and 88% specificity
for clinical depression (23). Scores of 5, 10, 15 and 20 represent cutpoints for
mild, moderate, moderately severe and severe depression. Any donor
revealing potentially worrisome psychological responseswas contacted by a
clinician from the relevant center and referred for additional help if deemed
necessary.
The Life Orientation Test-Revised (24) (LOT-R) identifies individuals who
maintain positive expectations in adversity. This measure utilizes six items
representing an optimistic trait or disposition toward optimism. Respon-
dents indicate their agreement with items on a 0–4 scale (‘‘strongly
disagree’’ to ‘‘strongly agree’’), with overall scores ranging from 0 to 24
and higher scores indicating optimism. Previous studies have demonstrated
acceptable internal consistency, convergent and discriminant validity (24).
Normative data were available for both medical and nonmedical
populations.
The 36-Item Short Form Health Survey (SF-36, version 2) (25), is a validated
and extensively used measure of quality of life (QOL) reflecting perceptions
over the previous 4 weeks. It is divided into two broad scales of behavioral
functioning, the Physical Component Score (PCS) and the Mental
Component Score (MCS). MCS was not included in the analysis because
of its strong correlation (r¼0.77) with the depression screening
instrument, the PHQ-9. Normative scores exist for the general population
and patients with medical conditions.
RELIVE study donation-specific questions
Utilizing questions described and used in the kidney donor literature (26),
members of the RELIVE consortium developed a set of questions on the
donation experience, attitudes about donation and donation-related relation-
ships. Specific topics included, donor recovery time (e.g., ‘‘How long after
donation surgery did it take you to return to your usual daily activities, such as
walking, driving a car or shopping for groceries?’’ Less than 3 months, 3–6
months, more than 6months or I never returned to my usual daily activities),
psychological care before and since donation, family support, relationship
with the recipient and recipient outcome and motivation for donation
including moral obligation which has been described as a three step process
that includes awareness of the effect of one’s actions on the welfare of
another person, ascribing responsibility to oneself rather than others and
accepting the moral norm at issue (26) (study questions available on
request). In a pilot study, the questionnaire was administered to 23 donors
who donated within the previous 1–4 years at two sites (Mayo and UAB) to
evaluate comprehension, flow and order of questions; modifications were
made prior to beginning the full study.
Control subjects for comparison with RELIVE donors with respect to
depression outcomes were derived from the publicly available National
Health and Nutrition Examination Survey (NHANES) 2009–2010 data (27).
NHANES participants were matched to RELIVE donors based on sex, race/
ethnicity, marital status, educational attainment, using an iteratively relaxed
match on age at the time of completing the survey (donors) or participating in
NHANES (up to 5 years) until at least one match was identified.
Statistical analysis
Descriptive information is reported as frequencies and percentages for
sample characteristics, and means and standard deviations for the PHQ-9,
LOT-R and PCS distributions. Scale scoreswere calculated if less than half of
the items were missing. Pearson correlations were calculated between
depression severity and optimism.
For regression analyses, all missing data were multiply imputed using
IVEware (http://www.isr.umich.edu/src/smp/ive/) to generate 10 imputation
sets. Thirty-eight donors had imputed values for the LOT-R, and 68 for the
PHQ-9. We also imputed missing values in educational attainment at
donation (n¼ 474), relationship to recipient (n¼ 7), BMI at donation (n¼ 49),
history of psychological difficulties (n¼ 72) and marital status (n¼ 46).
We used logistic regression to examine differences between donors who
were depressed at the time of questionnaire completion and those who
were not, using PHQ-9 scores at or above 10 as the threshold for clinically
relevant depression. Logistic regression was also used to examine
differences between donors who reported experiencing emotional,
psychological or substance abuse difficulties that they perceived to be a
result of donation and those who did not, and to examine differences
between donorswho sought help for such difficulties and thosewho did not.
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For each of these three outcomes, models were identified using a best
subsets approach, selecting the model with the highest likelihood score
statistic in which all covariates were statistically significant at p< 0.05. A
comparison of study participants to nonparticipating donors was also
performed using logistic regression.
Our study received approval by the following institutional review boards:
UAB, IRB approval number X070604010; UMN, IRB approval number
0905M66501; Mayo, IRB approval number 09-001345) and DCCs, IRB
approval number CR00032674 and protocol number HUM00004345.
Informed consent was provided by each participant.
Results
Cohort demographics and psychiatric characteristics
at the time of donation
The study cohort has previously been described (21). Of
6909 donors eligible for the study, 3470 acknowledged
contact. Of these, 2455 agreed to participate. Thus, of the
original cohort of potentially eligible subjects the response
rate was 36% and for those who acknowledged contact
(2455 of 3470) 71% completed the questionnaire. There
were 3439 who did not acknowledge contact due to
nonreceipt of communications or nonresponse to contact
efforts. Of those contacted, 931 declined to participate, 5
had language barriers and 79 withdrew consent or did not
return the questionnaire. RELIVE donors who were eligible
but did not participate (n¼ 4454) had lower educational
attainment at donation, donated more recently, were
younger at donation, were less likely to have a history of
depression before donation, and were more likely to be
black or another nonwhite race, male, separated, divorced
or widowed, and related to their recipient (all p< 0.05)
compared to donors who did participate.
Of the 2455 participants who completed the psychosocial
questionnaire (Table 1a, Table 1b; Supplemental Table S1):
93% were white, 61% were women and 52% were
40 years of age or older at donation. Over 41%were siblings
and 87% were related either genetically or by marriage to
their recipient. Of note, all categories of biologically related
or spousal donors were less likely to have a predonation
history of psychiatric difficulties than donors who were
not related to their recipients (such as friends, coworkers
or anonymous donors; 23% among unrelated donors
compared to 8% of parents, 7% of children, 7% of siblings,
11% of spouses and 12% of other related donors) based on
medical record review (all p< 0.05).
At donation, medical records indicated that over 90%of the
sample had never been on antidepressant or antianxiety
medication and had no history of alcoholism; 11% had past
or current pain problems (Table 1a). Depression (8%)
was the most common preexisting psychiatric condition
followed by anxiety (3%), but notably, subjects with bipolar
disorder (0.4%) had also donated (Table 1a). On the
questionnaire, 11% reported that they had been treated
for psychological problems prior to donation.
Psychiatric characteristics following donation
On the questionnaire, 4% noted psychiatric problems at
some time after donation; 2% sought treatment, and 1%
were in active treatment (Table 2a). Based on scores of 10
or greater on the PHQ-9, 8% of donors reported depressive
symptoms at the time of the survey (Table 2b) with
few reporting severe symptoms (Figure 1). The distribu-
tions of responses to PHQ-9 items are reported in
Supplemental Figure S1. RELIVE donors were less likely
to be taking medications for psychiatric issues including
depression or anxiety (12%) at the time of the survey
compared to 15% among matched NHANES controls
(p¼0.011) (Table 2b).
Optimism
As a group, donor responses (LOT-R mean (M)¼ 17.8,
standard deviation (SD)¼ 4.1) were similar to predonation
liver donors (M¼ 17.8, SD¼ 3.1) and more optimistic than
normative data from both a college-based sample
(M¼ 14.3) and medically ill sample (M¼ 15.2)
(Supplemental Figure S2) (24). The LOT-R was negatively
correlatedwith depression, with thosemore optimistic less
likely to report depression (r¼0.54, p<0.001).
Donor characteristics associated with self-report of
depression at the time of survey
Based on logistic regression (Table 3), depression in donors
(PHQ-910) was associated with a predonation history of
depression (p< 0.001), longer postdonation recovery time
(p¼0.009), greater financial burden (p¼ 0.013), stronger
agreement with the statement ‘‘It was my moral obligation
to donate’’ (p¼0.003), and emotional, psychological or
substance abuse problems following donation (p¼ 0.010).
After excluding donors who had a predonation history of
depression, many of the same characteristics remained
predictive of depression on the questionnaire.
The absence of depression symptoms (PHQ-9 9) was
associated with better physical health (measured as the
age- and sex-adjusted PCS from the SF-36, p< 0.001), older
age at donation (p¼0.002), higher optimism (measured as
higher scores on the LOT-R, p< 0.001), being employed
either full-time or part-time at the time of survey (p<0.001)
and being of white or European American race (p¼ 0.020).
Among donors without a history of depression before
donation, absence of depression symptoms was associat-
ed with better physical health (p< 0.001), higher optimism
(p<0.001) and being employed (p¼0.033).
In a separate analysis examining donation-specific ques-
tions, donors indicated whether they had experienced
emotional, psychological or substance abuse concerns as a
result of donation. Donors seeking help for these issues
after donation were more likely to have a predonation
history of depression (p¼0.022), and/or to have felt
depressed after surgery (p< 0.001) (Table 3), and were
more likely to report that their recipient’s graft had failed
Depressive Symptoms in Kidney Donors
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Table 1a: Characteristics of donors at the time of donation
Number of
participants
Percent of
participants
Number of
nonparticipants
Percent of
nonparticipants
All donors 2455 100.0 4454 100.0
Age at donation
Less than 30 years old 505 20.6 1242 27.9
30–39 years old 671 27.3 1484 33.3
40–49 years old 756 30.8 1129 25.3
50–59 years old 424 17.3 475 10.7
60 years old or older 99 4.0 117 2.6
Unknown or missing 0 0.0 7 0.2
Ethnicity
Non-Hispanic/non-Latino 2416 98.4 3608 81.0
Hispanic/Latino 31 1.3 88 2.0
Unknown or missing 8 0.3 758 17.0
Race
American Indian 16 0.7 46 1.0
Asian American 11 0.4 47 1.1
Black or African American 113 4.6 548 12.3
White or European American 2282 93.0 3703 83.1
Multi-racial 20 0.8 15 0.3
Unknown race 13 0.5 95 2.1
Gender
Female 1505 61.3 2421 54.4
Male 950 38.7 2033 45.6
Relationship of living donor to recipient
Biological, parent 450 18.3 930 20.9
Biological, child 316 12.9 672 15.1
Sibling 1011 41.2 1951 43.8
Biological, other relative 130 5.3 240 5.4
Nonbiological, spouse/partner 219 8.9 285 6.4
Nonbiological, friend 173 7.0 197 4.4
Nonbiological, other unrelated 149 6.1 163 3.7
Unknown 7 0.3 16 0.4
Surgical procedure
Open 1630 66.4 3244 72.8
Laparoscopic 822 33.5 1207 27.1
Unknown 3 0.1 3 0.1
Predonation historical measures
History of antidepressant use
Current 145 5.9 189 4.2
Previous 39 1.6 39 0.9
Never 2220 90.4 4147 93.1
Unknown 51 2.1 79 1.8
History of antianxiety drug use
Current 54 2.2 94 2.1
Previous 22 0.9 10 0.2
Never 2321 94.5 4263 95.7
Unknown 58 2.4 87 2.0
History of alcoholism or alcohol abuse
Yes 88 3.6 169 3.8
No 2275 92.7 4088 91.8
Unknown 92 3.7 197 4.4
History of illicit drug use
Yes 76 3.1 214 4.8
No 2124 86.5 3819 85.7
Unknown 255 10.4 421 9.5
History of chronic pain
Current 175 7.1 211 4.7
Previous 85 3.5 112 2.5
Never 2099 85.5 3940 88.5
Unknown 96 3.9 191 4.3
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(p¼0.007). Donors who reported emotional, psychological
or substance abuse concerns after donation were more
likely to have reported history of drug use at the predonation
evaluation (p¼0.010), history of chronic pain prior to
donation (p¼ 0.014), feeling that once the surgery was
over they did not receive attention (p< 0.001), and were
more likely to encounter postdonation re-hospitalization
(p<0.001) or medical complications not requiring hospitali-
zation (p< 0.001). Nonsignificant findings for all models are
provided in Supplemental Table S2.
Overall, most donors did not have a history of depression,
did not report emotional, psychological or substance abuse
difficulties after donation, and did not report depression
(PHQ-9<9) at follow-up (Figure 2). However, donors who
did report depression at the postdonation survey tended
to report having difficulties after donation, and also tended
to have a history of depression before donation.
Discussion
This study presents results from a cross-sectional survey
of kidney donors’ self-reports of depressive symptoms,
combined with predonation data on history of depression,
use of psychiatric medications and other characteristics.
We also tested potential predictors of depressive symp-
toms. For most donors, we were able to affirm that kidney
donation did not confer an increased prevalence of
depression. We did identify a small subset of donors who
Table 1: Continued
Number of
participants
Percent of
participants
Number of
nonparticipants
Percent of
nonparticipants
History of psychiatric difficulties
Unknown 72 2.9 111 2.5
None of the following 2141 87.2 4022 90.3
Depression 199 8.1 244 5.5
Anxiety 71 2.9 115 2.6
Bipolar 9 0.4 7 0.2
PTSD 0 0.0 7 0.2
Other psychiatric difficulties 26 1.1 48 1.1
Before your donation, had you ever been treated for emotional, psychological or substance abuse difficulties? (Collected on self-report
QOL questionnaire)
Yes 264 10.8 n/a –
No 2149 87.5 – –
Missing 42 1.7 – –
PTSD, post traumatic stress disorder; QOL, quality of life.
Table 1b: Characteristics of donors at quality of life questionnaire
completion (5–48 years after donation)
n %
All donors 2455 100.0
Age at survey completion
Less than 30 years old 20 0.8
30–39 years old 125 5.1
40–49 years old 433 17.6
50–59 years old 865 35.2
60–69 years old 673 27.4
70–79 years old 274 11.2
80 years old or older 65 2.6
Educational attainment at survey completion
Unknown or missing 13 0.5
Less than high school 66 2.7
High school 497 20.2
Some college, vo-tech or associate degree 920 37.5
Bachelor’s degree 510 20.8
Graduate degree 449 18.3
Marital status at survey completion
Missing 13 0.5
Married or living together 1852 75.4
Separated, divorced or widowed 449 18.3
Never married 141 5.7
Work status at survey completion
Missing 34 1.4
Working full-time for pay 1272 51.8
Working part-time for pay 299 12.2
Not working for pay at present
(not unemployed)
770 31.4
Unemployed 80 3.3
Table 2a: Psychological difficulties at quality of life questionnaire
completion (n¼2455, 5–48 years after donation)
Donor-reported perception of complications
because of donation
Donors
n %
Emotional, psychological or substance abuse
difficulties
98 4.0
Sought professional help for emotional,
psychological or substance abuse difficulties
60 2.4
Currently treated for emotional, psychological or
substance abuse difficulties
28 1.1
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reported an increase of depressive symptoms. Thus our
findings from the RELIVE study suggest that long-term
psychiatric morbidity following kidney donation occurs, but
affects a minority of donors. Factors that contributed to an
increased report of depressive symptoms following kidney
donation included longer recovery time, increased financial
burden, feeling a moral obligation to donate, being younger
at donation, being of nonwhite race, lower physical QOL
and having lower self-reported optimism. A history of
depression at the time of donation was also associated
with later depression, which might be expected given the
potential for relapse in individuals from the general
populationwith a history of depression. Additionally, reports
of rehospitalization and medical complications were asso-
ciated with donor perception of increased emotional,
psychological or substance abuse problems related to
donation. Not surprisingly, current unemployed or non-
employed status was associated with current depression.
Depression risk factors have been reported for donors (28).
Unlike our findings, Lentine et al, utilizing donor billing data
to identify antidepressant use as an indicator of depressive
symptomatology (6), reported higher rates of depression in
US white donors. Qualitative research and retrospective
studies note an association between recipient outcomes
and adverse emotional outcomes from donation (12).
Although RELIVE donors whose recipients lost their grafts
or died were more likely to have obtained professional help
for emotional, psychological or substance abuse concerns,
we did not find that graft failure led to increased reports of
depressive symptoms long-term.
In concurrence with our results, other studies suggest that
donors experience less depression or a nonsignificant
increase in depression symptoms (7,29,30), better social
function, less bodily pain and more vitality than controls or
patients undergoing nephrectomy for medical reasons (31).
Stable psychiatric conditions were not associated with
significant worsening of symptoms at the time of donor
surgery (32). Our research supports the existing literature
that suggests a high score for optimism sets the stage for
better overall outcomes in medical populations (19,20).
The characteristics of nonrelated donors have been the
focus of increased attention by the medical community (1)
and increased rates of donation by nonbiologically related
donors over the last five decades have been reported (22).
Interestingly, the higher proportions of preexisting psychi-
atric disorders in nonrelated donors highlights the need for
increased monitoring for depressive symptoms both pre-
and postdonor surgery in nonrelated donors.
Based on these findings, social workers, psychologists and
psychiatrists evaluating donors may wish to provide
increased support to donors who have the potential for a
higher prevalence of depression or have a lower thres-
hold for advising these donors about potential adverse
psychiatric outcomes. Thus far, interventions to increase
the resilience of donors has not been the focus of research.
New modalities including mindfulness-based stress reduc-
tion interventions, more frequent monitoring of mood
symptoms postdonation, and problem-solving strategies to
address financial stressors potentially could help alleviate
the stress of undergoing donor surgery. Additionally,
interventions such as motivational interviewing to explore
donor ambivalence, possibly related to social obligation as a
motivation to donate, has resulted in improved outcomes
in other donor populations (33). This may be especially
valuable for donor advocates wishing to assist donors in
assessing whether they have sufficiently considered the
risks and benefits of donation, to balance feeling compelled
to donate by societal values.
Table 2b: Depression outcomes at QOLquestionnaire completion
(5–48 years after donation)
Donors
NHANES
matches
n % %
Depression (10 PHQ-9) 190 7.8 7.0
Major depression based on PHQ criteria1 100 4.1 3.8
On medication for depression, anxiety or
other psychological disorders2
298 12.1 14.6
Reported percentages are percentages of donors with nonmissing
data; 23 donors were missing PHQ-9 scores. Percentages of
matched NHANES participants were calculated using NHANES
2009–2010, imputing PHQ-9 items among participants who were
missing less than half of the 9 items.
NHANES, National Health and Nutrition Examination Survey; PHQ,
Patient Health Questionnaire; QOL, quality of life.
1Major depressionwas defined as a depressive response to at least
five items, at least one of which is in the first two items.
2Measure was significantly different between RELIVE donors and
age, sex, race, ethnicity and education matched NHANES sample.
RELIVE donors were significantly less likely to be on antidepres-
sant medication than similar individuals who participated in
NHANES 2009–2010 (chi-square¼6.5, p¼0.011). RELIVE, Renal
and Lung Living Donors Evaluation Study.
Figure 1: Histogram of Patient Health Questionnaire-9
Depression Scores in kidney donors 5–48 years after donation.
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The main strengths of our study are the long interval from
donation to postdonation survey, the large sample size and
the diverse geographic and multicenter population. This
study addressed the frequency of donor self-reported
depression using a standardized rating scale widely used to
screen for depression and donors’ self-report of adverse
psychological sequelae of donation. Further, we investigat-
ed donors’ reports of the attribute of optimism, which may
be an important protective factor against the future
development of depressive symptoms.
The challenge of contacting eligible donors up to 50 years
after their surgery was formidable; in spite of multiple
attempts, only 50% of those identified through medical
records could be contacted by study staff. Differences in
characteristics between respondents and nonrespondents
Table 3: Results of logistic regression predicting psychological difficulties and depression 5–48 years after donation
Outcome Predictor OR Low CI High CI p-Value
Depression at QOL questionnaire (PHQ-910; c-statistic¼0.90)
History of depression: yes (ref: no) 2.55 1.53 4.26 <0.001
Emotional, psychological or substance abuse difficulties as a result
of donation
2.36 1.23 4.54 0.010
Race: nonwhite (ref: white) 2.00 1.11 3.59 0.020
Postdonation recovery time for daily activities (<3 months to never1) 1.74 1.15 2.64 0.009
Donation caused a financial burden 1.32 1.06 1.65 0.013
It was my moral obligation to donate 1.23 1.07 1.41 0.003
PCS, age and sex adjusted, per 1/2 standard deviation 0.79 0.72 0.87 <0.001
Age at donation, per 10 years 0.75 0.62 0.89 0.002
LOT-R 0.73 0.70 0.77 <0.001
Employed full- or part-time at survey completion (ref: not employed,
unemployed)
0.48 0.32 0.72 <0.001
Depression at QOL questionnaire (PHQ-910) among donors without a history of depression (c-statistic¼0.90)
Emotional, psychological or substance abuse difficulties as a result
of donation
2.21 1.05 4.66 0.037
Postdonation recovery time for daily activities (<3 months to never1) 1.90 1.21 2.98 0.005
Donation caused a financial burden 1.41 1.12 1.78 0.004
It was my moral obligation to donate 1.35 1.16 1.58 <0.001
PCS, age and sex adjusted, per 1/2 standard deviation 0.74 0.67 0.82 <0.001
LOT-R 0.73 0.69 0.77 <0.001
Employed full- or part-time at survey completion (ref: not employed,
unemployed)
0.63 0.41 0.96 0.033
‘‘Did you obtain professional help for emotional, psychological or substance abuse concerns that were a result of your donation?’’ (c-
statistic¼0.86)
I felt depressed for a while after the surgery (strongly disagree to
strongly agree)
2.83 2.32 3.46 <0.001
History of depression: yes (ref: no, unknown) 2.33 1.13 4.82 0.022
Graft failure (including recipient death) 2.25 1.25 4.06 0.007
‘‘Did you have any emotional, psychological or substance abuse difficulties that were the result of your donation?’’ (c-statistic¼0.79)
Rehospitalization or additional hospitalization days 3.23 1.90 5.48 <0.001
History of drug use: yes (ref: no, unknown) 3.02 1.31 6.98 0.010
Medical complication not requiring hospitalization 2.81 1.77 4.43 <0.001
Race: nonwhite (ref: white) 2.01 1.01 4.02 0.047
History of chronic pain predonation: yes (ref: no, unknown) 2.00 1.15 3.48 0.014
Once the surgery was over, no one really paid much attention to me
(strongly disagree to strongly agree)
1.46 1.23 1.75 <0.001
My family or friends supported me throughout the donor surgery 0.78 0.63 0.96 0.020
Only covariates that were significant (p<0.05) were included in the final models.
CI, confidence interval; LOT-R, LifeOrientation Test-Revised;OR, odds ratio; PHQ, Patient HealthQuestionnaire; PCS, Physical Component
Score (higher score is better); QOL, quality of life.
1Response categories for postdonation recovery included: ‘‘less than 3 months’’; ‘‘3–6 months’’; ‘‘more than 6 months’’; and ‘‘I never
returned to my usual daily activities.’’
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might have biased our estimated prevalence of depression,
although regression-based predicted probabilities estimat-
ed the bias at only 1%.
The RELIVE sample was not as racially and ethnically
diverse as the complete living kidney donor population in
the United States during the same time period, and tended
to be older, more likely to be biologically related to their
recipient (21,34) and likely to be employed.We did not have
standardized predonation data for depressive symptoms
or in-person subject interviews postdonation. We used
standardized instruments to evaluate for depression and
QOL, and used donation specific questions drawn from
prior studies (26), and tested for flow of instruments in a
separate limited sample of donors. Cognitive interviewing
identified a few minor wording improvements and was
deemed complete (reaching saturation) after 23 donor
interviews. Our study did not collect predonation data
prospectively and relied in part on recall by study subjects of
psychosocial complications that potentially occurred years
earlier, around the time of donation. The reliability of
retrospective assessments of psychological difficulties
shortly after donation is unclear as it is possible that these
reports could be conditioned by psychological difficulties
that are present at the time of survey completion. In the
survey research and cognitive psychology literature, this
phenomenon is referred to as retroactive interference (35).
The possibility of this type of recall error does undermine
somewhat, the defensibility of our statements relating to
the temporality of baseline versus current psychological
stress. Readers should interpret and act upon our study
findings with this potential limitation in mind.
Conclusions
This study provides a valuable window into the donor
experience using validated instruments to examine the
factors contributing to risk for depression years following
donation.We believe these datawill provide reassurance to
donors and clinicians that the experience of donation, often
in the setting of a loved one’s illness, does not increase
long-term depressive symptoms for most donors. Donors
who had good mental health predonation were unlikely
to develop depression in the years following donation.
Specific historical features did predict risk for long-term
adverse outcomes and identification predonation may
facilitate interventions that can improve donor recovery.
We found that donors as a group were more likely to be
optimistic in disposition which may further protect them
from future depression. Further studies to addresswhether
interventions would enhance the experience of higher risk
donors and studies on the impact of recipient outcomes on
donors could ultimately improve the donor experience.
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